Biotech company Affigen pulls in $17 mln Series A
St. Louis, Missouri-based Affigen, a biotechnology company that develops therapeutics targeting cell lineage-specific tumor proteins, has closed $17 million in Series A financing. Black Beret Life Sciences led the round on behalf of its affiliate BBLS Immunotherapy LLC.
22 February 2017•1 min read
